Literature DB >> 3276999

Buprenorphine detoxification from opioid dependence: a pilot study.

T R Kosten1, H D Kleber.   

Abstract

Sixteen opioid dependent patients were assigned to treatment with buprenorphine for one month at three doses--2 mg (n = 10), 4 mg (n = 4), 8 mg (n = 2). Treatment retention was excellent--only one patient left due to withdrawal symptoms. Illicit opioid use was infrequent, with only 22% of the urines containing illicit opioids. Although buprenorphine dose was not associated with retention or illicit opioid use, patterns of withdrawal symptoms differed among dosage groups during the 30 day study. The 4 mg group had a substantial decline in symptoms, while the other two groups did not. Symptom levels were comparable to those during successful clonidine detoxification and much lower than those found in clonidine failures.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3276999     DOI: 10.1016/0024-3205(88)90454-7

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  14 in total

Review 1.  Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.

Authors:  Paolo Mannelli; Kathleen S Peindl; Tong Lee; Kamal S Bhatia; Li-Tzy Wu
Journal:  Curr Drug Abuse Rev       Date:  2012-03

Review 2.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

3.  A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers.

Authors:  Stacey C Sigmon; Kelly E Dunn; Kathryn Saulsgiver; Mollie E Patrick; Gary J Badger; Sarah H Heil; John R Brooklyn; Stephen T Higgins
Journal:  JAMA Psychiatry       Date:  2013-12       Impact factor: 21.596

4.  HS-599: a novel long acting opioid analgesic does not induce place-preference in rats.

Authors:  R Lattanzi; L Negri; E Giannini; H Schmidhammer; J Schutz; G Improta
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

Review 5.  Buprenorphine for managing opioid withdrawal.

Authors:  Linda Gowing; Robert Ali; Jason M White; Dalitso Mbewe
Journal:  Cochrane Database Syst Rev       Date:  2017-02-21

Review 6.  Drugs of abuse--opiates.

Authors:  W Ling; D R Wesson
Journal:  West J Med       Date:  1990-05

7.  Brief buprenorphine detoxification for the treatment of prescription opioid dependence: a pilot study.

Authors:  Stacey C Sigmon; Kelly E Dunn; Gary J Badger; Sarah H Heil; Stephen T Higgins
Journal:  Addict Behav       Date:  2008-11-24       Impact factor: 3.913

Review 8.  Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy.

Authors:  Mark K Greenwald; Sandra D Comer; David A Fiellin
Journal:  Drug Alcohol Depend       Date:  2014-08-19       Impact factor: 4.492

9.  Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers.

Authors:  Sandra D Comer; Maria A Sullivan; Robert A Whittington; Suzanne K Vosburg; William J Kowalczyk
Journal:  Neuropsychopharmacology       Date:  2007-06-20       Impact factor: 7.853

10.  Opioid detoxification via single 7-day application of a buprenorphine transdermal patch: an open-label evaluation.

Authors:  Ryan K Lanier; Annie Umbricht; Joseph A Harrison; Elie S Nuwayser; George E Bigelow
Journal:  Psychopharmacology (Berl)       Date:  2008-03-09       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.